Open Accessibility Menu

Clinical Trial Information

A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma
  • Category: Liver
  • Status: Active
  • Starts: Oct 12, 2023
  • Stage: III
  • Trial Number: D910VC00001
  • Principal Investigator: Prajwol Pathak, M.D.

    Research Nurse: Wendy Blount, RN, MSN

Description of Trial:

This is a Phase III, parallel, randomized, open-label, sponsor-blinded, 3-arm, multicenter, international study assessing the efficacy and safety of durvalumab + tremelimumab + TACE with or without lenvatinib compared with TACE alone in participants with locoregional HCC not amenable to curative therapy (eg, surgical resection, transplantation, or ablation).

For more information, click here